
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. FDA has granted orphan drug designation to BrainEver's product BREN-02, the recombinant human homeoprotein Engrailed 1, for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Recombinant Human Homeoprotein Engrailed 1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
